Interleukin-2 - 330T>G genetic polymorphism associates with prognosis following surgery for thoracic esophageal squamous cell cancer

Annals of Surgical Oncology

Volumn 18, Issue 7, 2011, Pages 1995-2002

  Motoyama, Satoru ^a   Miura, Masatomo ^b   Hinai, Yudai ^b   Maruyama, Kiyotomi ^a   Usami, Shuetsu ^a   Yoshino, Kei ^a   Nakatsu, Toshinobu ^a   Saito, Hajime ^a   Minamiya, Yoshihiro ^a   Ogawa, Jun Ichi ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 4;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; THORACIC ESOPHAGEAL SQUAMOUS CELL CANCER; THORAX CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; SURVIVAL RATE; TH1 CELLS; TH2 CELLS; THORACIC NEOPLASMS; TREATMENT OUTCOME;

EID: 80051544018     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1553-2     Document Type: Article

References (28)

1. Kranzfelder M, Büchler P, Lange K, Friess H. Treatment options for squamous cell cancer of the esophagus: a systematic review of the literature. J Am Coll Surg. 2010;210:351-9.
2. Penman ID, Henry E. Advanced esophageal cancer. Gastrointest Endosc Clin N Am. 2005;15:101-16. (Pubitemid 39539231)
3. Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg. 2004;78:1177-83. (Pubitemid 39303830)
4. Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, et al. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvanttreated gastric carcinoma. Eur J Cancer. 2009;45:3326-35.
5. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol. 2008;19:1734-41.
6. Schöndorf T, Eisele L, Göhring UJ, Valter MM, Warm M, Mallmann P, et al. The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients. Tumour Biol. 2004;25:306-12. (Pubitemid 40082335)
7. Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2008;8:129-38. (Pubitemid 351411549)
8. Lagmay JP, London WB, Gross TG, Termuhlen A, Sullivan N, Axel A, et al. Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res. 2009;15:5234-9.
9. Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, et al. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol. 2007;30: 252-7. (Pubitemid 46884144)
10. Sarbia M, Stahl M, von Weyhern C, Weirich G, Pühringer-Oppermann F. The prognostic significance of genetic polymorphisms (methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, thymidilate synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer. 2006;94:203-7. (Pubitemid 43151536)
11. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006;24:3789-98. (Pubitemid 46628477)
12. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9: 798-809.
13. Onoé K, Yanagawa Y, Minami K, Iijima N, Iwabuchi K. Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol Res. 2007;38:319-32. (Pubitemid 47574916)
14. Ross OA, Curran MD, Meenagh A, Williams F, Barnett YA, Middleton D, et al. Study of age-association with cytokine gene polymorphisms in an aged Irish population. Mech Ageing Dev. 2003;124:199-206. (Pubitemid 36293929)
15. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFNgamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol. 2000;61:863-6.
16. Hall MA, McGlinn E, Coakley G, Fisher SA, Boki K, Middleton D, et al. Genetic polymorphism of IL-12 p40 gene in immunemediated disease. Genes Immun. 2000;1:219-24.
17. Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kawashima T, et al. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy. 1998;28:449-53. (Pubitemid 28215767)
18. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999;30:526-30. (Pubitemid 29357520)
19. Hyngstrom JR, Posner MC. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol. 2010;101:299-304.
20. Udagawa H. Chemoradiotherapy: its effectiveness, toxicity, and perspective in the treatment of esophageal cancer. Ann Thorac Cardiovasc Surg. 2009;15:359-61.
21. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9:532-62. (Pubitemid 26366537)
22. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775-87. (Pubitemid 351707693)
23. D'Souza WN, Lefrancois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol. 2003;171:5727-35. (Pubitemid 37467187)
24. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991;353:858-61. (Pubitemid 21912642)
25. John S, Turner D, Donn R, Sinnott P, Worthington J, Ollier WE, et al. Two novel biallelic polymorphisms in the IL-2 gene. Eur J Immunogenet. 1998;25:419-20. (Pubitemid 29037579)
26. Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, Di- Mercurio BS, Koziol DE, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti- CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation. 2001;72:1444-50. (Pubitemid 33015773)
27. Matesanz F, FedetzM, Leyva L,Delgado C, FernandezO,AlcinaA. Effects of the multiple sclerosis associated -330 promoter polymorphism in IL2 allelic expression. J Neuroimmunol. 2004;148: 212-7. (Pubitemid 38229573)
28. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol. 2000;46: 52-61.